Published in Hepatology on September 01, 1996
Hepatitis B virus biology. Microbiol Mol Biol Rev (2000) 7.58
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Virus dynamics and drug therapy. Proc Natl Acad Sci U S A (1997) 3.63
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut (2000) 2.16
Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol (2001) 2.14
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest (2001) 2.05
Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol (2001) 1.98
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother (1997) 1.94
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol (2003) 1.80
A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci U S A (2005) 1.72
Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol (2000) 1.45
Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother (1998) 1.45
Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob Agents Chemother (1999) 1.41
Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations. J Clin Microbiol (1998) 1.34
Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol (1999) 1.26
Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents Chemother (2002) 1.26
Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother (2002) 1.21
Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1998) 1.21
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother (2001) 1.18
Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother (1999) 1.16
Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest (1999) 1.10
The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob Agents Chemother (1998) 1.09
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother (2001) 1.09
Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J Virol (2001) 1.09
Use of PCR in resolving diagnostic difficulties potentially caused by genetic variation of hepatitis B virus. J Clin Pathol (1998) 1.05
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother (2002) 1.05
Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol (2001) 1.03
Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine. Antimicrob Agents Chemother (1998) 1.02
Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J Biol Chem (2008) 0.99
Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol (1999) 0.97
Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother (1998) 0.97
Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. Antimicrob Agents Chemother (1998) 0.95
Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon (2012) 0.95
Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler. J Clin Microbiol (2001) 0.94
Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil. World J Hepatol (2010) 0.93
Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol (2012) 0.89
Properties of monoclonal antibodies directed against hepatitis B virus polymerase protein. J Virol (1999) 0.89
Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg (1998) 0.88
YMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation. World J Gastroenterol (2005) 0.86
Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS One (2010) 0.86
Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. J Virol (2002) 0.85
Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles. Antimicrob Agents Chemother (1997) 0.83
Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China. Med Sci Monit (2011) 0.83
High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial. BMC Gastroenterol (2005) 0.83
Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. BMC Microbiol (2012) 0.82
Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis. Hepat Mon (2013) 0.81
Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients. J Gastroenterol (2006) 0.81
Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. World J Gastroenterol (2007) 0.81
Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob Agents Chemother (2002) 0.81
Changes in the antigenicity of a hepatitis B virus mutant stemming from lamivudine therapy. Antimicrob Agents Chemother (2000) 0.80
Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B. Antimicrob Agents Chemother (2000) 0.80
Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains. Dig Dis Sci (2004) 0.79
Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol (2007) 0.77
Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening. Antimicrob Agents Chemother (2003) 0.77
Pretreatment and on-treatment predictors of viral breakthrough in lamivudine therapy for chronic hepatitis B. Hepatol Int (2008) 0.77
Expression and purification of a functional human hepatitis B virus polymerase. World J Gastroenterol (2010) 0.76
Hepatitis B virus infection and liver transplantation. Gut (1997) 0.76
Resistance to lamivudine therapy: is there more than meets the eye? Gut (2005) 0.75
Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B. Saudi J Gastroenterol (2012) 0.75
Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) (2012) 0.75
Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection? Gut (1999) 0.75
Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients. Clin Exp Nephrol (2013) 0.75
Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. Dig Dis Sci (2008) 0.75
Degradation of polychlorinated biphenyls by two species of Achromobacter. Can J Microbiol (1973) 7.70
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
Diagnostic importance of changes in circulating concentrations of immunoreactive trypsin. Lancet (1977) 3.43
Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. Aliment Pharmacol Ther (2014) 3.39
Transmission of HBsAg from mother to infant in four ethnic groups. Br Med J (1978) 3.23
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation (1997) 2.60
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Cholangiography in the jaundiced patient. Gut (1976) 2.44
A randomized trial of percutaneous transhepatic cholangiography with the Chiba needle versus endoscopic retrograde cholangiography for bile duct visualization in jaundice. Gastroenterology (1976) 2.25
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut (2000) 2.16
Clinical profile and outcome of swine flu in Indian children. Indian Pediatr (2010) 2.14
Serum trypsin concentrations in diabetes mellitus. Br Med J (1978) 2.09
Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ (1996) 2.04
Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med (1981) 1.96
The pathology of hepatitis C. Hepatology (1992) 1.92
The complete sequence of hepatitis E virus genotype 4 reveals an alternative strategy for translation of open reading frames 2 and 3. J Gen Virol (2000) 1.89
EDRF coordinates the behaviour of vascular resistance vessels. Nature (1987) 1.86
Clinical spectrum, investigations and treatment of Budd-Chiari syndrome. QJM (1996) 1.81
Causes and outcome of young infant admissions to a Kenyan district hospital. Arch Dis Child (2003) 1.81
Managing Budd-Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut (1999) 1.80
Acute polymyositis in an adult associated with Mycoplasma pneumoniae infection. Postgrad Med J (1990) 1.80
The slowing of gastric emptying by monosaccharides and disaccharides in test meals. J Physiol (1968) 1.79
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet (1996) 1.78
Hepatitis C virus transmitted by human bite. Lancet (1990) 1.77
Neurological complications following liver transplantation. Lancet (1987) 1.76
Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol (1998) 1.72
Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine (1995) 1.71
Wilson's disease with superimposed autoimmune features: report of two cases and review. J Gastroenterol Hepatol (2000) 1.70
Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. Lancet (1984) 1.67
Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med (1982) 1.67
Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut (1997) 1.66
Delay in presentation of symptomatic referrals to a breast clinic: patient and system factors. Br J Cancer (2000) 1.66
Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy. Lancet (2000) 1.66
Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut (2002) 1.65
Internal olefins to linear amines. Science (2002) 1.64
Clinical heterogeneity associated with deletions in the long arm of chromosome 15: report of 3 new cases and their possible genetic significance. Am J Med Genet (1987) 1.62
The complete nucleotide sequence of the genome of a hepatitis B virus isolated from a naturally infected chimpanzee. J Gen Virol (1988) 1.62
A divergent genotype of hepatitis E virus in Chinese patients with acute hepatitis. J Gen Virol (1999) 1.59
Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol (2005) 1.57
Radiological intervention in Budd-Chiari syndrome: techniques and outcome in 18 patients. Clin Radiol (1996) 1.57
A simple technique of umbilical port closure in laparoscopic cholecystectomy. Ann R Coll Surg Engl (1993) 1.56
Prevalence and diagnostic significance of fluid-fluid levels in soft-tissue neoplasms. Clin Radiol (2007) 1.56
Sulphoxidation and sulphation capacity in patients with primary biliary cirrhosis. J Hepatol (1995) 1.54
HBV DNA levels and transmission of hepatitis B by health care workers. J Clin Virol (2003) 1.54
Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet (1994) 1.53
Radio-frequency thermal ablation with NaCl solution injection: effect of electrical conductivity on tissue heating and coagulation-phantom and porcine liver study. Radiology (2001) 1.53
Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. J Clin Invest (1983) 1.52
Chronic pancreatitis: a cause of cholestasis. Gut (1977) 1.51
Prostatic infarction/infection in acute urinary retention secondary to benign prostatic hyperplasia. J Urol (1998) 1.49
Thalidomide in Crohn disease and the risk of peripheral neuropathy. J Pediatr Gastroenterol Nutr (2003) 1.49
Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure. Liver Transpl Surg (1997) 1.44
Pancreatic cholera due to production of gastric inhibitory polypeptide. Lancet (1972) 1.44
Amoebic appendicitis--a rare entity. J Pak Med Assoc (1994) 1.42
Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob Agents Chemother (1999) 1.41
Association of spinocerebellar disorders with cystic fibrosis or chronic childhood cholestasis and very low serum vitamin E. Lancet (1981) 1.40
Colonic Crohn's disease and use of oral contraception. Br Med J (Clin Res Ed) (1984) 1.40
Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements. Br J Obstet Gynaecol (1998) 1.40
Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet (2000) 1.39
Primary hepatic malignancy: the role of liver transplantation. Br J Surg (1990) 1.34
Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers. BMJ (1992) 1.32
Risks to surgeons and patients from HIV and hepatitis. BMJ (1993) 1.30
GSTM1 null polymorphism at the glutathione S-transferase M1 locus: phenotype and genotype studies in patients with primary biliary cirrhosis. Gut (1993) 1.30
Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol (2004) 1.28
Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis. J Lab Clin Med (1976) 1.27
Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis (2008) 1.26
Kinetics of acute hepatitis B virus infection in humans. J Exp Med (2001) 1.26
Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev (2006) 1.25
Urinary tract pathogens and resistance pattern. J Clin Pathol (2010) 1.24
Antenatal screening for carriers of hepatitis B virus. BMJ (1995) 1.24
Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis. Eur J Gastroenterol Hepatol (1997) 1.24
Biopsy findings in cases of rejection of liver allograft. J Clin Pathol (1985) 1.24
Antimicrobial susceptibilities and plasmid contents of Neisseria gonorrhoeae isolates from commercial sex workers in Dhaka, Bangladesh: emergence of high-level resistance to ciprofloxacin. J Clin Microbiol (1999) 1.24
The importance of seeking ALMS1 mutations in infants with dilated cardiomyopathy. J Med Genet (2005) 1.23
Long-arm deletion of 19-20 chromosomes. Lancet (1972) 1.23
Evidence for the presence of hepatitis E virus in pigs in the United Kingdom. Vet Rec (2004) 1.23
Electron microscopic localization of herpesvirus-type particles in Marek's disease. J Virol (1968) 1.22
Endoscopic retrograde cholangiopancreatography in the diagnosis of jaundice associated with ulcerative colitis. Gastroenterology (1974) 1.22
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat (2012) 1.19
Prevention of perinatal transmission of hepatitis B virus (HBV): a comparison of two prophylactic schedules. J Med Virol (1991) 1.19
HSV shedding. Antiviral Res (2004) 1.18
Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM (2000) 1.18
Fulminant hepatic failure caused by tuberculosis. Gut (1995) 1.18
Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology (2004) 1.17
Precore and core mutations in HBV from individuals in India with chronic infection. J Med Virol (1995) 1.17
Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. N Engl J Med (1987) 1.17
A sustainable community-based arsenic mitigation pilot project in Bangladesh. Int J Environ Health Res (2001) 1.17
Sclerosing cholangitis associated with multifocal fibrosis: a case report. Gut (1992) 1.17
High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol (1999) 1.17
Detection of alpha-foetoprotein messenger RNA in human hepatocellular carcinoma and hepatoblastoma tissue. Br J Cancer (1986) 1.17
Transplantation of the liver in adults and children with fulminant hepatic failure. J Hepatol (1988) 1.16
Diversity of genotypes of hepatitis C virus in southern India. J Gen Virol (1995) 1.16
Recurrence of autoimmune hepatitis after liver transplantation. Transplantation (1999) 1.16
The epidemiology and spectrum of surgical care in district hospitals of Pakistan. Am J Public Health (1987) 1.16